IL17A and psoriasis: Our study demonstrated that the oral administration of 10 mg/kg DXM alleviated the symptoms of psoriasis and inhibited keratinocyte proliferation by decreasing proinflammatory cytokines and IL-17- and IL-22-producing γδ T cell production.